ArticleBlood and lymphatic cancer : targets and therapy2026
Efficacy and Safety of an Orelabrutinib-Based Oral Induction Regimen in Central Nervous System Lymphoma: A Real-World Study.
Article in Blood and lymphatic cancer : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of an orelabrutinib-based RBTL regimen (rituximab, orelabrutinib, temozolomide, and pomalidomide) as an induction strategy for patients with central nervous system lymphoma (CNSL). Patients and methods: We retrospectively analyzed 40 patients with CNSL treated at the Affiliated Hospital of Qingdao University between April 2022 and January 2025, including 28 newly diagnosed and 12 relapsed/refractory patients. RBTL was administered as induction therapy, followed by individualized subsequent treatment, including high-dose methotrexate (HD-MTX)-based therapy, radiotherapy, autologous stem cell transplantation, or maintenance therapy. The primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety. Results: Forty patients were evaluable for safety and 38 for efficacy. All 38 efficacy-evaluable patients received subsequent individualized therapy after RBTL induction, including HD-MTX-based therapy, radiotherapy, ASCT, or orelabrutinib maintenance. After RBTL induction, the ORR was 86.8% (33/38), including a complete response/unconfirmed complete response (CR/CRu) rate of 36.8%. After subsequent therapy, the best ORR was 94.7% (36/38), with a CR/CRu rate of 63.2%. With a median follow-up of 18.5 months, the 12-month PFS and OS rates were 74.7% (95% CI, 61.6-90.6%) and 71.3% (95% CI, 57.7-88.2%), respectively. Treatment-emergent adverse events occurred in 92.5% of patients, and 7.5% discontinued treatment because of adverse events. One treatment-related death occurred in association with severe thrombocytopenia. Conclusion: RBTL showed encouraging activity and manageable toxicity as an induction strategy for CNSL. Because most evaluable patients received subsequent individualized therapy, durable disease control should be interpreted in the context of the overall sequential treatment strategy. Larger prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.